Funda Meric‐Bernstam

105.6k total citations · 15 hit papers
876 papers, 35.9k citations indexed

About

Funda Meric‐Bernstam is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Funda Meric‐Bernstam has authored 876 papers receiving a total of 35.9k indexed citations (citations by other indexed papers that have themselves been cited), including 458 papers in Oncology, 392 papers in Cancer Research and 269 papers in Molecular Biology. Recurrent topics in Funda Meric‐Bernstam's work include Cancer Genomics and Diagnostics (194 papers), Breast Cancer Treatment Studies (178 papers) and HER2/EGFR in Cancer Research (120 papers). Funda Meric‐Bernstam is often cited by papers focused on Cancer Genomics and Diagnostics (194 papers), Breast Cancer Treatment Studies (178 papers) and HER2/EGFR in Cancer Research (120 papers). Funda Meric‐Bernstam collaborates with scholars based in United States, United Kingdom and Spain. Funda Meric‐Bernstam's co-authors include Ana M. González-Angulo, Kelly K. Hunt, Gabriel N. Hortobágyi, Henry M. Kuerer, Gordon B. Mills, Filip Jankú, Gildy V. Babiera, Timothy A. Yap, Elizabeth A. Mittendorf and Merrick I. Ross and has published in prestigious journals such as Nature, Cell and The Lancet.

In The Last Decade

Funda Meric‐Bernstam

836 papers receiving 35.2k citations

Hit Papers

PD-L1 Expression in Tripl... 2009 2026 2014 2020 2014 2018 2014 2009 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-L1 Expression in Triple-Negative Breast Cancer
    2014 1.1k citations Elizabeth A. Mittendorf, Anne V. Philips et al. Cancer Immunology Research profile →
  2. Targeting the PI3K pathway in cancer: are we making headway?
    2018 787 citations Filip Jankú, Timothy A. Yap et al. profile →
  3. Clonal evolution in breast cancer revealed by single nucleus genome sequencing
    2014 711 citations Ken Chen, Funda Meric‐Bernstam et al. profile →
  4. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
    2009 684 citations Funda Meric‐Bernstam, Gabriel N. Hortobágyi et al. profile →
  5. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
    2013 525 citations Ana M. González-Angulo, Funda Meric‐Bernstam et al. Clinical Cancer Research profile →
  6. Targeting the mTOR Signaling Network for Cancer Therapy
    2009 522 citations Funda Meric‐Bernstam, Ana M. González-Angulo profile →
  7. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 432 citations Funda Meric‐Bernstam et al. profile →
  8. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
    2019 383 citations Funda Meric‐Bernstam, Kanwal Raghav et al. profile →
  9. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. profile →
  10. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    2021 251 citations Milind Javle, Razelle Kurzrock et al. profile →
  11. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
    2021 240 citations Funda Meric‐Bernstam et al. Clinical Cancer Research profile →
  12. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
    2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →
  13. Antibody-drug conjugates in lung cancer: dawn of a new era?
    2023 80 citations Timothy A. Yap, Funda Meric‐Bernstam et al. profile →
  14. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
    2024 68 citations Senthil Damodaran, Funda Meric‐Bernstam et al. profile →
  15. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
    2024 43 citations Funda Meric‐Bernstam, Joon Oh Park et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Funda Meric‐Bernstam 17.5k 14.6k 11.9k 7.4k 7.1k 876 35.9k
Luis A. Díaz 14.6k 0.8× 13.9k 1.0× 13.1k 1.1× 14.1k 1.9× 6.5k 0.9× 419 40.3k
Clifford A. Hudis 23.6k 1.3× 14.1k 1.0× 8.2k 0.7× 4.0k 0.5× 6.9k 1.0× 509 39.7k
Charles Swanton 12.8k 0.7× 12.7k 0.9× 13.0k 1.1× 3.4k 0.5× 8.5k 1.2× 325 30.6k
Stuart J. Schnitt 12.2k 0.7× 15.7k 1.1× 6.8k 0.6× 11.0k 1.5× 3.4k 0.5× 377 30.5k
Lee M. Ellis 16.7k 1.0× 9.6k 0.7× 17.6k 1.5× 2.9k 0.4× 6.5k 0.9× 361 38.8k
Daniel F. Hayes 27.3k 1.6× 21.8k 1.5× 13.3k 1.1× 6.5k 0.9× 9.7k 1.4× 412 47.9k
Josep Tabernero 34.3k 2.0× 8.9k 0.6× 14.4k 1.2× 9.5k 1.3× 14.7k 2.1× 1.1k 50.8k
Steven Gallinger 16.8k 1.0× 7.0k 0.5× 7.1k 0.6× 8.6k 1.2× 3.8k 0.5× 354 25.6k
Ignacio I. Wistuba 16.4k 0.9× 9.0k 0.6× 16.8k 1.4× 2.7k 0.4× 12.4k 1.8× 687 36.0k
Giuseppe Viale 29.3k 1.7× 26.1k 1.8× 13.1k 1.1× 12.6k 1.7× 9.5k 1.3× 768 55.3k

Countries citing papers authored by Funda Meric‐Bernstam

Since Specialization
Citations

This map shows the geographic impact of Funda Meric‐Bernstam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Funda Meric‐Bernstam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Funda Meric‐Bernstam more than expected).

Fields of papers citing papers by Funda Meric‐Bernstam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Funda Meric‐Bernstam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Funda Meric‐Bernstam. The network helps show where Funda Meric‐Bernstam may publish in the future.

Co-authorship network of co-authors of Funda Meric‐Bernstam

This figure shows the co-authorship network connecting the top 25 collaborators of Funda Meric‐Bernstam. A scholar is included among the top collaborators of Funda Meric‐Bernstam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Funda Meric‐Bernstam. Funda Meric‐Bernstam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Evans, Kurt W., Maria Gabriela Raso, Dhruv Chachad, et al.. (2025). Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. Molecular Cancer Therapeutics. 24(9). 1402–1414. 1 indexed citations
2.
Akçakanat, Argun, Xiaofeng Zheng, Tae‐Beom Kim, et al.. (2021). Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research. 27(11). 3243–3252. 17 indexed citations
3.
Meric‐Bernstam, Funda, Rastislav Bahleda, Cinta Hierro, et al.. (2021). Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery. 12(2). 402–415. 171 indexed citations breakdown →
4.
Friedman, Claire F., John D. Hainsworth, Razelle Kurzrock, et al.. (2021). Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery. 12(3). 654–669. 56 indexed citations
5.
Subbiah, Vivek, Pete Anderson, Kalevi Kairemo, et al.. (2019). Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research. 25(13). 3802–3810. 32 indexed citations
6.
Hess, Kenneth R., Filip Jankú, Nora Sánchez, et al.. (2019). Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research. 26(8). 1924–1931. 40 indexed citations
7.
Kurnit, Katherine C., Ecaterina E. Dumbrava, Beate C. Litzenburger, et al.. (2018). Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clinical Cancer Research. 24(12). 2719–2731. 41 indexed citations
8.
Bugano, Diogo Diniz Gomes, Kenneth R. Hess, Denis L. Jardim, et al.. (2017). Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clinical Cancer Research. 23(15). 4020–4026. 17 indexed citations
9.
Loree, Jonathan M., Allan Andresson Lima Pereira, Michael Lam, et al.. (2017). Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research. 24(5). 1062–1072. 201 indexed citations
10.
Kurnit, Katherine C., Ann M. Bailey, Jia Zeng, et al.. (2017). “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource. Cancer Research. 77(21). e123–e126. 29 indexed citations
11.
Evans, Kurt W., Erkan Yuca, Argun Akçakanat, et al.. (2017). A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research. 23(21). 6468–6477. 48 indexed citations
12.
Tang, Chad, Kenneth R. Hess, Suzanne E. Davis, et al.. (2016). Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clinical Cancer Research. 23(6). 1407–1413. 9 indexed citations
13.
Goswami, Rashmi S., Keyur P. Patel, Rajesh R. Singh, et al.. (2015). Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research. 21(11). 2644–2651. 59 indexed citations
14.
Ganesan, Prasanth, Stacy L. Moulder, J. Jack Lee, et al.. (2014). Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics. 13(12). 3175–3184. 29 indexed citations
15.
Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations
16.
Mittendorf, Elizabeth A., Anne V. Philips, Funda Meric‐Bernstam, et al.. (2014). PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research. 2(4). 361–370. 1065 indexed citations breakdown →
17.
Jardim, Denis L., Chad Tang, Débora De Melo Gagliato, et al.. (2014). Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research. 20(24). 6336–6345. 65 indexed citations
18.
Meric‐Bernstam, Funda, Garrett M. Frampton, Jaime Ferrer-Lozano, et al.. (2014). Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics. 13(5). 1382–1389. 68 indexed citations
19.
Meric‐Bernstam, Funda, Argun Akçakanat, Huiqin Chen, et al.. (2012). PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clinical Cancer Research. 18(6). 1777–1789. 171 indexed citations
20.
Arun, Banu, Kristen J. Vogel, Adriana López, et al.. (2009). High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prevention Research. 2(2). 122–127. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luis A. Díaz Breakdown of academic impact, for papers by Clifford A. Hudis Breakdown of academic impact, for papers by Charles Swanton Breakdown of academic impact, for papers by Stuart J. Schnitt Breakdown of academic impact, for papers by Lee M. Ellis Breakdown of academic impact, for papers by Daniel F. Hayes Breakdown of academic impact, for papers by Josep Tabernero Breakdown of academic impact, for papers by Steven Gallinger Breakdown of academic impact, for papers by Ignacio I. Wistuba Breakdown of academic impact, for papers by Giuseppe Viale
Rankless by CCL
2026